Emily is a former editorial intern at Spectrum and a graduate student in New York University’s Science, Health & Environmental Reporting Program. Previously, Emily worked on aging research in Boston, Massachusetts. She has a B.A. in chemistry from Williams College in Williamstown, Massachusetts.
Emily Harris
Former news intern
Spectrum
From this contributor
Prenatal exposures; Angelman trial suspension; autistic adult well-being
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Prenatal exposures; Angelman trial suspension; autistic adult well-being
Null and Noteworthy: Modified MRI; father findings
This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.
Null and Noteworthy: Modified MRI; father findings
Null and Noteworthy: Reinforcing rigor; medication medley
This month’s newsletter highlights findings on the use of three medication types during pregnancy.
Null and Noteworthy: Reinforcing rigor; medication medley
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
Explore more from The Transmitter
Personalized medicine; astroglia organoids; fast track for fragile X drug
Here is a roundup of autism-related news and research spotted around the web for the week of 20 January.
Personalized medicine; astroglia organoids; fast track for fragile X drug
Here is a roundup of autism-related news and research spotted around the web for the week of 20 January.
Neuroscientists need to do better at explaining basic mental health research
The knowledge gap between scientists, health-care professionals, policymakers and people with mental health conditions is growing, slowing the translation of basic science to new treatments. Like lawyers learning to present a case to the court, scientists should learn to educate nonscientists about their findings.
Neuroscientists need to do better at explaining basic mental health research
The knowledge gap between scientists, health-care professionals, policymakers and people with mental health conditions is growing, slowing the translation of basic science to new treatments. Like lawyers learning to present a case to the court, scientists should learn to educate nonscientists about their findings.
Dose, scan, repeat: Tracking the neurological effects of oral contraceptives
We know little about how the brain responds to oral contraceptives, despite their widespread use. I am committed to changing that: I scanned my brain 75 times over the course of a year and plan to make my data openly available.
Dose, scan, repeat: Tracking the neurological effects of oral contraceptives
We know little about how the brain responds to oral contraceptives, despite their widespread use. I am committed to changing that: I scanned my brain 75 times over the course of a year and plan to make my data openly available.